" class="no-js "lang="en-US"> Sanofi Archives - Medtech Alert
Saturday, June 22, 2024

Sort by:

Date

Top Post

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]

Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis

Regeneron Pharmaceuticals and Sanofi today announced that the European Commission (EC) has approved Dupixent (dupilumab) […]

Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Eosinophilic Esophagitis

Regeneron Pharmaceuticals and Sanofi today announced that the European Commission (EC) expanded the marketing authorization […]

Skyhawk Announces Collaboration Agreement with Sanofi for Oncology and Immunology Targets

Skyhawk Therapeutics, Inc. today announced the signing of an exclusive worldwide collaboration agreement with Sanofi […]

Sanofi-GSK Next-generation COVID-19 Booster Delivers Strong Immune Response Against Variants of Concern, Including Omicron

Sanofi today reports data from two trials, VAT02 Cohort 2 and COVIBOOST VAT013, conducted with […]

Sanofi and Seagen Announce Collaboration to Develop and Commercialize Multiple Novel Antibody-drug Conjugates

Sanofi and Seagen Inc. (Nasdaq:SGEN) today announced an exclusive collaboration agreement to design, develop, and commercialize antibody-drug conjugates […]

Sanofi Announces €300 Million Collaboration with Blackstone Life Sciences to Advance an Innovative Treatment for Multiple Myeloma

Sanofi and Blackstone (NYSE: BX) today announced a strategic, risk-sharing collaboration under which funds managed […]

NovAliX Signs Partnership Agreement to Design and Screen Sanofi’s New DNA-Encoded Libraries

NovAliX, a Contract Research Organization (CRO) specializing in drug research and development, today announces its […]

Sanofi Invests $180 Million Equity in Owkin ’s Artificial Intelligence and Federated Learning to Advance Oncology Pipeline

Sanofi announced today an equity investment of $180 million and a new strategic collaboration with […]

Mirati Therapeutics to Collaborate with Sanofi on Phase 1/2 Study Evaluating Combination of adagrasib with a SHP2 Inhibitor in KRAS G12C-mutated Lung Cancer

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced a non-exclusive clinical collaboration agreement […]

Sanofi to Acquire Translate Bio; Advances Deployment of mRNA Technology Across Vaccines and Therapeutics Development

As part of Sanofi’s endeavor to accelerate the application of messenger RNA (mRNA) to develop […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more